Welcome to our dedicated page for Nextcure news (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on Nextcure stock.
NextCure, Inc. (NASDAQ: NXTC) is a clinical-stage biopharmaceutical company focused on developing targeted therapies, including antibody-drug conjugates, for cancer patients who do not respond to, or have disease progression on, current treatments. The NXTC news feed highlights company announcements that trace the progress of its pipeline and corporate strategy.
Investors and followers of NextCure can use this page to review updates on its lead ADC programs, SIM0505 and LNCB74. News items include business updates and quarterly financial results, where the company discusses clinical trial status, dose escalation progress and plans for proof-of-concept data readouts in advanced solid tumors. Press releases also cover preclinical findings for programs such as NC605 in osteogenesis imperfecta and NC181 in Alzheimer’s disease models.
NXTC news frequently addresses strategic partnerships and licensing agreements, such as the collaboration with Simcere Zaiming for SIM0505 and the co-development arrangement with LigaChem Biosciences Inc. for LNCB74. Readers will also find coverage of scientific presentations at major conferences, including trial-in-progress posters and preclinical data presentations.
In addition, the feed includes capital markets and corporate developments reported by NextCure, such as private placements of common stock and pre-funded warrants, reverse stock split implementation, and changes in executive leadership. These disclosures provide context on how the company finances its research and manages its listing on the Nasdaq Global Select Market.
By reviewing the NXTC news page regularly, users can follow the evolution of NextCure’s oncology-focused pipeline, its non-oncology preclinical efforts, and key corporate decisions that may influence the company’s development plans and financial position.
NextCure (Nasdaq: NXTC) presented promising preclinical data for NC605, their novel anti-Siglec-15 antibody treatment for osteogenesis imperfecta (OI), also known as brittle bone disease. The study demonstrated that NP159 (the murine version of NC605) improved bone microarchitecture and reduced fracture incidence compared to anti-sclerostin treatment in OI mice.
Key findings showed that weekly treatment with 20 mg/kg of NP159 increased cortical and trabecular bone mineral density, tissue mineral density, and cortical thickness while decreasing trabecular separation compared to control groups. The research was conducted in collaboration with Dr. Cathleen Raggio from Hospital for Special Surgery, New York. NextCure is now seeking financial partners to advance NC605 toward an IND submission within 12-18 months.
NextCure (NXTC) and LigaChemBio announced they will present a trial in progress poster for LNCB74, their B7-H4 targeted antibody-drug conjugate (ADC), at the upcoming ASCO Annual Meeting in Chicago. The Phase 1 study is evaluating LNCB74 as a monotherapy for advanced solid tumors, including platinum-resistant ovarian cancer, treatment-refractory breast cancer, endometrial cancer, biliary tract cancer, and squamous non-small cell lung cancer.
The first-in-human study includes dose escalation, safety, and biomarker backfills, followed by randomized dose expansion/optimization phases. The trial is currently in the dose escalation phase. According to NextCure's CMO, B7-H4 is an attractive target due to its high expression in multiple tumor types and limited expression in normal tissues. LNCB74 has shown promising preclinical results with a superior safety profile and potent anti-tumor activity.
NextCure (Nasdaq: NXTC), a clinical-stage biopharmaceutical company focused on cancer therapy development, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The presentation is scheduled for Thursday, April 10th, at 8:45 am ET.
Investors and interested parties can access a live audio webcast through the Investors section of NextCure's website. The presentation recording will remain available on the company's website for 30 days following the event.
NextCure (NXTC) has reported its full year 2024 financial results and provided key business updates. The company has completed cohort 1 of the Phase 1 trial for LNCB74, their B7-H4 ADC cancer therapeutic, in February 2025 and plans to initiate backfill cohorts in H2 2025.
Financial highlights include cash position of $68.6 million, expected to fund operations into H2 2026. The company reported a net loss of $55.7 million for 2024, improved from $62.7 million in 2023. R&D expenses decreased to $41.5 million from $47.9 million, while G&A expenses reduced to $15.7 million from $19.7 million.
In pipeline developments, NextCure received FDA acceptance for LNCB74's IND application in December 2024 and dosed first patient in January 2025. The company is also seeking partners for two preclinical non-oncology programs: NC181 for Alzheimer's disease and NC605 for osteogenesis imperfecta.
NextCure (NXTC) has announced the dosing of its first patient in a Phase 1 study of LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) designed to treat multiple cancers. This milestone follows the FDA's clearance of the Investigational New Drug application for LNCB74 in December 2024.
The study aims to evaluate the safety, tolerability, and preliminary anti-tumor activity of LNCB74, which is being developed in partnership with LigaChem Biosciences through a collaboration and co-development agreement.
NextCure announced the FDA's acceptance of an Investigational New Drug (IND) application for LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) developed in partnership with LigaChem Biosciences. This acceptance allows NextCure to proceed with a Phase 1 clinical trial to evaluate LNCB74 as a treatment for multiple cancers.
The company's CEO, Michael Richman, highlighted that this milestone aligns with their focus on advancing their ADC program. The IND application was supported by preclinical data demonstrating LNCB74's differentiation from other B7-H4-targeting ADCs, suggesting potential transformative treatment outcomes for patients.
NextCure (Nasdaq: NXTC) has announced its participation in the 36th Annual Piper Sandler Healthcare Conference in New York City. The clinical-stage biopharmaceutical company, focused on developing novel cancer therapies, will engage in a fireside chat on Thursday, December 5, at 12:00 pm ET.
The event will feature a live audio webcast accessible through the Investors section of NextCure's website. The presentation will remain archived on the company's website for 30 days following the event.
NextCure announced preclinical data showing that NC605, their anti-Siglec-15 antibody, enhanced quality bone generation with improved mechanical properties in mice with Osteogenesis Imperfecta (OI). The study used NP159, a surrogate antibody to NC605, at 20 mg/kg dosage. Key results showed 90% of male and 80% of female treated mice had no fractures, compared to 85% and 55% in control groups. Both sexes demonstrated increased trabecular and cortical tissue mineral density. Male mice specifically showed increased trabecular bone volume and cortical thickness, resulting in improved mechanical bone strength.